Literature DB >> 19762191

Hepatic iron overload and risk of hepatocellular carcinoma in cirrhosis.

P Nahon1, N Ganne-Carrié, J-C Trinchet, M Beaugrand.   

Abstract

Iron accumulation in the liver is considered to be a co-factor for progression of liver disease. Iron overload can enhance the effects of oxidative stress and influence the natural history of patients with cirrhosis, exposing them to a higher risk of hepatocellular carcinoma. The results of clinical studies designed to assess the impact of liver iron content on the risk of tumor development have remained controversial for some time. It is known that common factors can affect both liver iron overload and the risk of cancer, necessitating multivariate analyses of these features in large cohorts of cirrhotic patients. Furthermore, the causes and consequences of hepatic iron overload appear to depend on the cause of the underlying liver disease. Thus, the only solid evidence of a relationship between liver iron overload and event occurrence has come from longitudinal studies conducted in homogeneous cohorts of patients with cirrhosis. So far, the available data suggest that iron accumulation in the liver is an independent risk factor for hepatocellular carcinoma in patients with alcoholic cirrhosis and/or nonalcoholic hepatosteatosis, but not in those with viral hepatitis C cirrhosis. Copyright 2009 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19762191     DOI: 10.1016/j.gcb.2009.07.032

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  6 in total

1.  Association of Serum Ferritin with Diabetes and Alcohol in Patients with Non-Viral Liver Disease-Related Hepatocellular Carcinoma.

Authors:  Rohan C Siriwardana; Madunil A Niriella; Anuradha Dassanayake; Dileepa Ediriweera; Bhagya Gunetilleke; Thenuka Sivasundaram; Janaka de Silva
Journal:  Liver Cancer       Date:  2017-08-29       Impact factor: 11.740

2.  Quantitative susceptibility mapping (QSM) minimizes interference from cellular pathology in R2* estimation of liver iron concentration.

Authors:  Jianqi Li; Huimin Lin; Tian Liu; Zhuwei Zhang; Martin R Prince; Kelly Gillen; Xu Yan; Qi Song; Ting Hua; Xiance Zhao; Miao Zhang; Yu Zhao; Gaiying Li; Guangyu Tang; Guang Yang; Gary M Brittenham; Yi Wang
Journal:  J Magn Reson Imaging       Date:  2018-03-22       Impact factor: 4.813

Review 3.  Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols.

Authors:  Danijel Galun; Dragan Basaric; Marinko Zuvela; Predrag Bulajic; Aleksandar Bogdanovic; Nemanja Bidzic; Miroslav Milicevic
Journal:  World J Hepatol       Date:  2015-09-18

Review 4.  MicroRNAs and liver cancer associated with iron overload: therapeutic targets unravelled.

Authors:  Catherine M Greene; Robert B Varley; Matthew W Lawless
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

5.  Tumor-induced disorder of iron metabolism in major organs: a new insight from chemical speciation of iron.

Authors:  Rujie Chen; Guangcun Chen
Journal:  J Int Med Res       Date:  2017-07-18       Impact factor: 1.671

6.  Safranal induces DNA double-strand breakage and ER-stress-mediated cell death in hepatocellular carcinoma cells.

Authors:  Ala'a Al-Hrout; Amphun Chaiboonchoe; Basel Khraiwesh; Chandraprabha Murali; Badriya Baig; Raafat El-Awady; Hamadeh Tarazi; Amnah Alzahmi; David R Nelson; Yaser E Greish; Wafaa Ramadan; Kourosh Salehi-Ashtiani; Amr Amin
Journal:  Sci Rep       Date:  2018-11-16       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.